Phenylketonuria …

Neurogenetic Disorders

Updated 05.30.2023
Released 03.30.1995
Expires For CME 05.30.2026

Phenylketonuria

Authors: Kimberly A Chapman MD PhD, Debra S Regier MD PhD

See Contributor Disclosures

Editor: Barry Wolf MD PhD

Phenylketonuria

In This Article

Quick Link

Introduction

Overview

In this article, the authors review the history of the discovery of phenylketonuria, one of the oldest known inborn errors of metabolism, and review the development of dietary treatment and neonatal screening for this disorder. The pathophysiologic mechanisms that are thought to cause central nervous system damage are discussed. New FDA-approved treatments and treatments in trial are revolutionizing the treatment of phenylketonuria in the 21st century.

Key points

	• Phenylketonuria is caused by deficient activity of phenylalanine hydroxylase, an enzyme in the intermediary metabolism of the amino acid, phenylalanine, and is one of the most common inborn errors of metabolism.
	• Phenylketonuria is inherited as an autosomal recessive disorder.
	• Neonatal screening for phenylketonuria allows for the early detection and treatment of infants with the disorder.
	• Dietary therapy of phenylketonuria is based on restriction of dietary phenylalanine intake and largely prevents the major manifestations of the disorder, including profound developmental disability and seizures, but there are difficulties with lifelong adherence to the diet that may lead to cognitive impairment, particularly problems with executive functioning.
	• Novel therapeutic approaches for phenylketonuria include sapropterin dihydrochloride treatment of a subset of patients who are responsive to the drug, large neutral amino acid supplementation to block phenylalanine uptake into brain, and enzyme substitution therapy with polyethylene glycol-conjugated phenylalanine ammonia lyase.

Historical note and terminology

In 1934, Følling reported a compound in the urine of two developmentally disabled individuals that reacted with ferric chloride to produce a deep green color. He subsequently identified this compound as phenylpyruvic acid in the urine of 10 developmentally delayed individuals (14). Penrose and Quastel named the disease "phenylketonuria” and first attempted dietary therapy (36). The metabolic defect in phenylketonuria was determined to be impaired hydroxylation of phenylalanine to tyrosine (21), and the liver enzyme phenylalanine hydroxylase was ultimately shown to be deficient in individuals with phenylketonuria (22). With the development of a simple bacterial inhibition assay, known as the Guthrie test (17), and along with the successful treatment by dietary restriction of phenylalanine using synthetic diets (05), neonatal screening and early treatment were introduced. Most neonatal screening programs have now discontinued the use of the Guthrie test to detect elevated phenylalanine concentrations in favor of the faster, more sensitive tandem mass spectrometry method that also detects several other amino acidopathies. The human gene encoding phenylalanine hydroxylase was cloned in 1983 (57).

With the successful treatment of phenylketonuria, a group of individuals were identified who, despite dietary restriction of phenylalanine, had progressive neurologic disease and were designated as having "malignant phenylketonuria." These children were found to have a deficiency of one of the enzymes of tetrahydrobiopterin metabolism. Tetrahydrobiopterin is a necessary cofactor for phenylalanine hydroxylase, tyrosine-3-hydroxylase, and tryptophan-5-hydroxylase (the latter two are rate-limiting enzymes in the synthesis of catecholamines and serotonin, respectively), and all forms of nitric oxide synthase. In addition to having elevated phenylalanine, children with defects in the metabolism of tetrahydrobiopterin exhibit deficiency of biogenic amine neurotransmitters in the central nervous system. Treatment by dietary phenylalanine restriction alone is not successful, but must be combined with tetrahydrobiopterin replacement and administration of L-DOPA and 5-hydroxytryptophan to address the neurotransmitter deficiencies.

Nomenclature for this group of inborn errors of metabolism can be confusing because of the great phenotypic variability (42). The 2014 American College of Medical Genetics and Genomics guidelines on the diagnosis and management of phenylalanine hydroxylase deficiency recommend that the term “phenylalanine hydroxylase (PAH) deficiency” be used to describe all affected individuals who previously have been described as having phenylketonuria. In this review, we will use the historical term “phenylketonuria.” This supports the concept that there is a spectrum of phenylalanine hydroxylase deficiency. This guideline recommends a unifying nomenclature and, therefore, refers to the spectrum of phenylalanine hydroxylase deficiency, not specifically relying on the blood phenylalanine concentration; although the guidelines recognize that the most severe form is still likely to be referred to as “classical phenylketonuria” in many settings. Historically, those with the most severe phenylalanine hydroxylase deficiency had untreated blood phenylalanine concentrations typically greater than 1200 μmol/l (mean normal concentration: 60 µmol/l) and were called “classical phenylketonuria”. On the milder side of the spectrum, patients with untreated blood phenylalanine concentrations greater than normal concentrations, but less than 1200 μmol/l, were previously described as having hyperphenylalaninemia.

Clinical manifestations

Presentation and course

Untreated phenylketonuria produces the gradual onset of profound developmental disability in most, but not all, individuals (35; 39). Intelligence testing reveals that 50% to 70% of individuals with untreated phenylketonuria have IQs below 35, and 88% to 90% below 65, but 2% to 5% of untreated children have intelligence in the normal range. Other clinical features of untreated children include fair pigmentation for ethnicity, eczema, a musty odor, microcephaly, autistic behaviors, and abnormal hand movements. Neurologic features include seizures (26%), spasticity, hyperreflexia, and tremors (35).

Diagnosis of all forms of hyperphenylalaninemia is based on finding elevated whole blood phenylalanine concentrations by newborn screening, with confirmation of hyperphenylalaninemia by quantitative analysis of plasma amino acids. Any children identified with hyperphenylalaninemia should then be tested for a biopterin pathway enzyme deficiency by measuring urinary pterin concentration ratios (biopterin and neopterin) and by measuring enzymes involved in biopterin metabolism in blood.

Thus, it is important that children with seizures born in areas that do not perform newborn screening be assessed for phenylalanine hydroxylase deficiency. The current newborn screening programs are very effective at identifying phenylalanine hydroxylase deficiency, but as with any screening program, clinical suspicion of this disorder should be high for children with a phenotype consistent with untreated disorder. Individuals usually have good outcomes if they are identified early and treated (42). Individuals with phenylketonuria may still have some long-term impairments in some executive functioning (44) and can develop some neurologic symptoms (32).

Prognosis and complications

Prognosis in untreated phenylketonuria is poor, although 2% to 5% of untreated children will have normal intelligence. Even with treatment, children and adults can have mild neurologic issues, such as attention and mental health concerns.

Clinical vignette

A 3.3 kg male infant was born at term. Newborn metabolic screening by tandem mass spectrometry performed at age 24 hours revealed a whole blood phenylalanine concentration of 460 µmol/L (normal is less than190 µmol/L). The ratio of phenylalanine concentration to tyrosine (the product of the phenylalanine hydroxylase reaction) concentration was elevated at 4.1 (normal is less than 3.0), indicating a high likelihood of phenylalanine hydroxylase-deficient hyperphenylalaninemia. Quantitative plasma amino acid analysis at 7 days of age demonstrated a plasma phenylalanine concentration of 1250 µmol/L. Biopterin studies were normal. These results confirmed that the infant had hyperphenylalaninemia due to phenylalanine hydroxylase deficiency and he was classified as having classical phenylketonuria. Dietary therapy based on restriction of dietary phenylalanine intake was initiated.

Some clinicians also perform sequencing of the phenylalanine hydroxylase gene to confirm the diagnosis and to attempt to predict the severity of phenylalanine intolerance and predict response to sapropterin. However, genotype-phenotype correlations are limited.

Biological basis

	• Autosomal recessively inherited
	• Deficiency of phenylalanine hydroxylase
	• Accumulate phenylalanine
	• Deficient in tyrosine
	• Only 2% to 5% of untreated children have normal IQ

Etiology and pathogenesis

Phenylketonuria is due to an autosomal recessively inherited deficiency of phenylalanine hydroxylase (located on chromosome 12q). More than 500 different mutations have been reported. Most individuals with phenylketonuria are compound heterozygotes, which provides for great variability in phenotypes.

The enzyme is a homotetramer, and interactions of different mutant gene products differentially affect the final conformation of the enzyme resulting in variability of residual enzyme activity.

Phenylalanine hydroxylase deficiency produces elevated phenylalanine concentrations in plasma, CSF, and urine as a direct result of the inability to convert phenylalanine to tyrosine. Tyrosine concentrations are low relative to the elevated phenylalanine concentrations, but are often within the normal range because of sufficient dietary tyrosine intake. When hydroxylation of phenylalanine is blocked, there is increased transamination of phenylalanine to phenylpyruvic acid, which is readily excreted in urine. Numerous other minor metabolites, such as phenylacetic acid, phenyllactic acid, and phenylethylamine, collectively known as phenylketones, are also excreted.

Neurologic outcomes in untreated patients. The nervous system is the organ primarily affected in untreated phenylketonuria, with developmental delay as its phenotype. Mutation analysis (genotyping) may help predict dietary phenylalanine tolerances, but plasma phenylalanine concentrations (biochemical phenotype) may not predict the presence or degree of developmental delay (clinical phenotype), if untreated. Historically, 2% to 5% of untreated children exhibit normal IQ (35; 39).

It is hypothesized that more than blood phenylalanine concentrations are involved in producing the developmental delay. A saturable carrier, the system L transporter, mediates facilitated diffusion of neutral amino acids, including phenylalanine, tyrosine, and tryptophan, across the blood-brain barrier. In vivo magnetic spectroscopy reveals that the correlation of blood and brain phenylalanine concentrations varies considerably among individuals (55). Thus, significant differences in blood-brain barrier transport may underlie the individual vulnerability to the neurologic effects of phenylketonuria. Further data are needed before spectroscopic measurement of brain phenylalanine concentrations can be used clinically.

At normal physiologic concentrations of neutral amino acids in plasma, the system L neutral amino acid carrier is already nearly saturated and susceptible to competitive inhibition (15). The high concentrations of plasma phenylalanine in phenylketonuria inhibit the uptake of other neutral amino acids, such as tyrosine and tryptophan (34), and oral administration of large neutral amino acids, other than phenylalanine, to individuals with phenylketonuria can inhibit phenylalanine uptake into the brain (37). The characteristics of the neutral amino acid transporter are being utilized as a new treatment for phenylketonuria. Thus, biochemical effects of elevated phenylalanine concentrations in the brain are multiple and include direct inhibition of metabolic processes, generalized deficiency of neutral amino acids in brain leading to impaired protein synthesis, and specific tyrosine and tryptophan deficiencies leading to deficiencies of the neurotransmitters dopamine and serotonin. However, the precise molecular mechanism underlying the neuronal damage associated with hyperphenylalaninemia is not yet proven.

White matter disease is common in untreated phenylketonuria. Poser and van Bogaert were the first to recognize that these lesions are due to demyelination (41). In addition to demyelination, sometimes so severe as to be characterized as status spongiosis, there is gliosis. In gray matter of subjects with untreated phenylketonuria, there is neuronal loss, reduced size of neurons, and decreased dendritic processes on Purkinje cells (24).

Neurologic outcomes in treated patients. White matter changes may also be seen in individuals with phenylketonuria treated from birth. MRIs of the brain in treated children reveal increased signal on T2 images with decreased signal on T1 images, most prominently in parieto-occipital and periventricular white matter, with severe cases also involving more frontal areas (09). Current theories regarding the etiology of these MRI findings have been reviewed (01).

White matter abnormalities in a 7-year-old with phenylketonuria (MRI)

(Left) T2-weighted MRI reveals increased signal. (Right) T1-weighted MRI reveals decreased signal. (Contributed by Dr. Lane Rutledge.)

White matter abnormalities do not correlate with IQ, but do correlate with dietary control and plasma phenylalanine concentrations at time of imaging, and the changes may be reversible with improved dietary control (09; 26). Based on imaging characteristics, the white matter changes are suggestive of accumulation of a hydrophilic metabolite within cells without alteration of myelin structure (26). Diffusion tensor imaging (DTI) of 29 individuals with early-treated PKU at ages 6 to 35 years revealed widespread decreased white matter mean diffusivity in comparison to that of non-PKU controls; lower diffusivity was associated with higher blood phenylalanine concentrations and impaired executive function by formal assessments (02). These results suggest that white matter axonal integrity is maintained, but elevated phenylalanine concentrations are associated with impaired water diffusion in white matter.

Neurophysiologic evidence of abnormal brain function is also present. Maturation of EEG patterns is delayed in infants with phenylketonuria (11). Although development of EEG alpha activity is normal, slowing of background rhythms and increased paroxysmal activity is seen in some individuals and the incidence increases with age (38). Prolongation of sensory nerve conduction velocities and somatosensory evoked potentials, as well as prolonged latencies of visual and auditory evoked potentials, is reported in a significant number of adolescents with treated phenylketonuria (30). Supplementation with fish oil improved visual evoked potentials in 36 children with phenylketonuria (04). Early-treated phenylketonuria in adults frequently has nonprogressive brain white matter changes and, less consistently, cortical and subcortical grey matter alterations, which are associated with their degree of metabolic control (and age) (10).

Management

Therapy for all of the disorders with elevated phenylalanine concentrations requires a specialized clinic setting with dieticians, social services, psychologists, and metabolic specialists. The management team must be aware of the need for education of individuals with phenylketonuria and their families, of the psychological impact of a chronic disease, and of the financial constraints of expensive, but essential, treatments that may not be fully covered by health insurance.

Dietary treatments. The classic treatment of phenylketonuria is dietary restriction of phenylalanine to a degree that maintains plasma phenylalanine concentrations between 120 to 360 µmol/L yet provides for normal growth. Published recommendations have reiterated the need for lifelong, repetitive monitoring and strict control of blood phenylalanine concentration in order to prevent long-term neurologic complications and allow optimal neurobehavioral function (45; 50). This requires a very restrictive diet and can only be accomplished with the use of a synthetic phenylalanine-deficient formula. Breastfeeding in infancy is possible, but it must be significantly limited. Older versions of synthetic formulas are often poorly tolerated because of taste. This feature and the complexity of the diet lead to high rates of nonadherence to the prescribed restrictions, reaching as high as 75% of adolescents and adults with phenylketonuria in many centers (53). The majority of phenylalanine-deficient formulas and food are supplemented with free amino acids; these are often bitter tasting and may be metabolized less efficiently than whole proteins. Glycomacropeptide (GMP) is an abundant, naturally occurring protein in whey that lacks phenylalanine in its primary amino acid sequence; foodstuffs made with GMP are more palatable than traditional phenylalanine-free foods (28), and their use may be associated with improved bone health and metabolic stress, at least in a murine model of phenylketonuria, in comparison to a diet based on free amino acids (47; 48). The Genetic and Metabolic Dietitians International (GMDI) has published a set of guidelines of dietary recommendations that update in real time (33).

Treatment. The American College of Medical Genetics and Genomics guidelines recommend that every patient with phenylalanine hydroxylase deficiency undergo a trial with sapropterin dihydrochloride (Kuvan™ by BioMarin of Novato, California), a synthetic form of tetrahydrobiopterin (50). These recommendations are based on extensive studies showing the benefit of this treatment on phenylamine concentrations (18). Plasma phenylalanine concentrations decrease to below 600 µmol/L without dietary protein restriction in approximately 10% of adults taking sapropterin (10 mg/kg per day) (08). The percentage of “‘sapropterin-responsive”’ individuals may approach 20% if a higher dose, 20 mg/kg per day, is administered. Long-term efficacy of sapropterin therapy has been demonstrated in randomized, placebo-controlled, crossover trials in adults (27) and children (49) with phenylketonuria. In the latter trial, plasma phenylalanine concentrations decreased by at least 30% in approximately half of children with phenylketonuria although most still required some degree of dietary protein restriction and continued use of phenylalanine-free medical foods. Individuals with ‘milder’ degrees of phenylketonuria who naturally tolerate somewhat greater amounts of dietary protein are more likely to respond to sapropterin treatment, but surprisingly even a few individuals with very severe phenylketonuria exhibit lower plasma phenylalanine concentrations while on sapropterin therapy. Unfortunately, the phenylalanine hydroxylase genotype of the individual patient does not predict sapropterin responsiveness completely (27), and subjects’ response to sapropterin treatment can only be adequately assessed by measuring plasma phenylalanine concentrations repeatedly during a trial of daily sapropterin therapy lasting at least four weeks. Sapropterin is also approved for use during pregnancy in women who are responsive, but experience with this is still limited (23).

Another recommended therapeutic approach is to supply orally all of the large neutral amino acids, except phenylalanine, in order to compete with phenylalanine for transport into the brain, which is mediated by the neutral amino acid carrier at the blood-brain barrier (50). This therapy lowers brain phenylalanine concentrations and leads to improvements in EEG patterns of adults with hyperphenylalaninemia (37). With the addition of arginine and lysine to the neutral amino acid mix, some competition with phenylalanine uptake in the intestinal lumen may also be achieved resulting in decreased plasma phenylalanine concentrations (31). This therapy is not sufficiently robust to be routinely used in young children and is contraindicated in women during pregnancy because it does not block the systemic phenylalanine concentrations. Thus, the primary cohort for this treatment includes adolescents and adults who are unable to adhere to the protein-restricted diet.

In 2018, the FDA approved a phenylalanine ammonia lyase-polyethylene glycol (Pegvaliase ®) that is administered by subcutaneous injection for adults with phenylketonuria. This treatment underwent multiple trials and requires provider and dietitian management to optimize patient outcomes (29). Close management with a physician and dietitian is also needed because this medication has a high risk for anaphylaxis.

Currently, phase 2 clinical trials using PKU gene therapy are recruiting patients. More information can be accessed at the following website:Clinicaltrials.gov.

Outcomes

In treated individuals with phenylketonuria, prognosis is usually good, with normal intelligence. Individuals with phenylketonuria who maintain strict adherence to the diet have the best outcomes; most of those who discontinue the diet will exhibit a decline in IQ scores (19; 43). The severity of decrease in IQ score correlates with the duration off of the diet and the age when the diet was discontinued, with the poorest performance occurring in children who discontinued the diet before six years of age.

However, even children treated early and who successfully maintain their plasma phenylalanine concentrations within the targeted treatment range will likely exhibit mild executive impairment (13; 25). This topic has been the subject of intense research by multiple investigators seeking to define the cause(s) and to find a remedy for these issues; these ongoing efforts have been summarized in a series of review articles (56). Seemingly minor fluctuations in plasma phenylalanine concentrations in well-controlled individuals can interfere with neuropsychological function; younger children are especially sensitive to this effect (20). Even mild elevations of plasma phenylalanine concentrations chronically above the recommended treatment range may have detrimental effects on cognition (12). Some functions (cognitive flexibility, attention, and complex problem solving) have a strong negative correlation with elevated plasma phenylalanine concentrations at the time of testing (43). One theory is that there is dysfunction of prefrontal cortex, possibly due to dopamine depletion (13).

When assessed by their teachers, children with phenylketonuria are more likely to be rated as having more deviant behavior (mannerisms, anxiety, hyperactivity, and less social) than unaffected individuals, but are not rated as more aggressive or disobedient (46). Children with phenylketonuria are more likely to be treated with stimulant medications than unaffected individuals (03). Adolescents and adults with phenylketonuria show more depression, dependency, low frustration tolerance, and low self-esteem, and are prone to social withdrawal (54; 52). The incidence of these abnormalities correlates with duration of poor dietary compliance, but the symptoms often respond to renewed dietary phenylalanine restriction (52). Formal screening for psychiatric symptoms in adults with PKU reveals a high and previously underappreciated incidence of psychosis, paranoid ideation, obsessive-compulsive disorder, depression, and anxiety; both acute and chronic elevations of blood phenylalanine concentration are correlated with the occurrence of psychiatric symptoms (06). Individuals diagnosed and treated late (older than 3 months old), treated adults who have had difficulty with diet adherence, and even untreated adults with cognitive abnormalities who were born prior to the advent of newborn screening may significantly benefit from the favorable behavioral effects of a low-phenylalanine diet (16). It is clear that, even in well-controlled individuals, there are neuropsychological effects of elevated brain phenylalanine concentrations.

Neurologic deterioration, such as spasticity, tremor, and cognitive decline, has been reported in some affected adults (32). Minor neurologic abnormalities, such as tremors and fine motor difficulties, can be seen in fairly well controlled individuals with phenylketonuria; however, significant neurologic deterioration has only been reported in those with probable late treatment or with IQs of less than 80. This has not been seen in individuals treated early, except due to a concomitant vitamin B12 deficiency (07).

References

01: Anderson PJ, Leuzzi V. White matter pathology in phenylketonuria. Mol Genet Metab 2010;99(Suppl 1):S3-9. PMID 20123467
02: Antenor-Dorsey JA, Hershey T, Rutlin J, et al. White matter integrity and executive abilities in individuals with phenylketonuria. Mol Genet Metab 2013;109(2):125-31. PMID 23608077
03: Arnold GL, Vladutiu CJ, Orlowski CC, Blakely EM, DeLuca J. Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J Inherit Metab Dis 2004;27(2):137-43. PMID 15159644
04: Beblo S, Reinhardt H, Muntau AC, et al. Fish oil supplementation improves visual evoked potentials in children with phenylketonuria. Neurology 2001;57:1488-91. PMID 11673596
05: Bickel H, Gerrard J, Hickmans EM. Influence of phenylalanine intake on phenylketonuria. Lancet 1953;265(6790):812-3. PMID 13098090
06: Bilder DA, Burton BK, Coon H, et al. Psychiatric symptoms in adults with phenylketonuria. Mol Genet Metab 2013;108(3):155-60. PMID 23339767
07: Brenton DP, Pietz J. Adult care in phenylketonuria and hyperphenylalanemia: the relevance of neurological abnormalities. Eur J Pediatr 2000;159(Suppl 2):S114-20. PMID 11043157
08: Burton BK, Grange DK, Milanowski A, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis 2007;30(5):700-7. PMID 17846916
09: Cleary MA, Walter JH, Wraith JE, White F, Tyler K, Jenkins JP. Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change. J Pediatr 1995;127:251-5. PMID 7636650
10: De Giorgi A, Nardecchia F, Manti F, Campistol J, Leuzzi V. Neuroimaging in early-treated phenylketonuria patients and clinical outcome: A systematic review. Mol Genet Metab 2023;139(2):107588. PMID 37149991
11: De Giorgis GF, Nonnis E, Crocioni F, et al. Evolution of daytime quiet sleep components in early treated phenylketonuric infants. Brain Dev 1996;18:201-6. PMID 8836501
12: Diamond A. Phenylalanine levels of 6 to 10 mg/dl may not be as benign as once thought. Acta Paediatr Suppl 1994;407:89-91. PMID 7766969
13: Diamond A, Prevor MB, Callender G, Druin DP. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev 1997;62(4):i-v, 1-208. PMID 9421921
14: Folling A. Ueber Ausscheidung von Pheylbrenz-traubensaure uiden Harn als stoff wechselanomalie in verbindung mit Imbezillitat. Z Physiol Chem 1934;227:169-76.
15: Gardiner RM. Transport of amino acids across the blood-brain barrier: implications for treatment of maternal phenylketonuria. J Inherit Metab Dis 1990;13:627-33. PMID 2122125
16: Gassio R, Campistol J, Vilaseca MA, et al. Do adult patients with phenylketonuria improve their quality of life after introduction/resumption of a phenylalanine-restricted diet. Acta Paediatr 2003;92:1474-8. PMID 14971801
17: Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-43. PMID 14063511
18: Harding CO. New era in treatment for phenylketonuria: pharmacologic therapy with sapropterin dihydrochloride. Biologics 2010;4:231-6. PMID 20714359
19: Holtzman NA, Kronmal RA, Doorninch WV, Azen C, Kock R. Effect of age at loss of dietary control on intellectual performance and behavior of children with phenylketonuria. N Engl J Med 1986;314:593-8. PMID 3945244
20: Huijbregts S, De Sonneville M, Licht R, et al. Short-term dietary interventions in children and adolescents with treated phenylketonuria: Effects on neuropsychological outcome of a well-controlled population. J Inherit Metab Dis 2002;25:419-30. PMID 12555935
21: Jervis G. Studies on phenylpyruvic oligophrenia: the position of the metabolic error. J Biol Chem 1947;169:651-6. PMID 20259098
22: Jervis GA. Phenylpyruvic oligophrenia deficiency of phenylalanine-oxidizing system. Proc Soc Exp Biol Med 1953;82(3):514-5. PMID 13047448
23: Koch R. Maternal phenylketonuriaphenylketonuria and tetrahydrobiopterin. Pediatrics 2008;122(6):1367-8. PMID 19047257
24: Kornguth S, Gilbert-Barness E, Langer E, Hegstrand L. Golgi-Kopsch silver study of the brain of a patient with untreated phenylketonuria, seizures, and cortical blindness. Am J Med Genet 1992;44:443-8. PMID 1442885
25: Leuzzi V, Pansini M, Sechi E, et al. Executive function impairment in early-treated PKU subjects with normal mental development. J Inherit Metab Dis 2004;27:115-25. PMID 15159642
26: Leuzzi V, Tosetti M, Montanaro D, et al. The pathogenesis of the white matter abnormalities in phenylketonuria: a multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study. J Inherit Metab Dis 2007;30:209-16. PMID 17245558
27: Levy HL, Milanowski A, Chakrapani A, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuriaphenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007;370(9586):504-10. PMID 17693179
28: Lim K, van Calcar SC, Nelson KL, Gleason ST, Ney DM. Acceptable low-phenylalanine foods and beverages can be made with glycomacropeptide from cheese whey for individuals with PKU. Mol Genet Metab 2007;92(1-2):176-8. PMID 17644019
29: Longo N, Dimmock D, Levy H, et al. Evidence-and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria. Genet Med 2019;21(8):1851-67. PMID 30546086
30: Ludolph AC, Vetter U, Ullrich K. Studies of multimodal evoked potentials in treated phenylketonuriaphenylketonuria: the pattern of vulnerability. Eur J Pediatr 1996;155(Suppl 1):S64-8. PMID 8828613
31: Matalon R, Michals-Matalon K, Bhatia G, et al. Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis 2006;29:732-8. PMID 16988900
32: Merkel M, Berg D, Brüggemann N, et al. Characterisation and differential diagnosis of neurological complications in adults with phenylketonuria: literature review and expert opinion. J Neurol 2023. PMID 37081197
33: Southeast Regional Genetics Network. Nutrition Management Guidelines for PKU. Available at:https://managementguidelines.net/guidelines.php/90/PKU%20Nutrition%20Guidelines/Version%201.12. Accessed May 2023.
34: Oldendorf WH. Saturation of blood brain barrier transport of amino acids in phenylketonuria. Arch Neurol 1973;28:45-8. PMID 4734147
35: Paine RS. The variability in manifestations of untreated patients with phenylketonuria (phenylpyruvic aciduria). Pediatrics 1957;50:290-302. PMID 13452670
36: Penrose L, Quastel JH. Metabolic studies in phenylketonuria. Biochem J 1937;31:266-76. PMID 16746333
37: Pietz J, Kreis R, Rupp A, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clinic Invest 1999;103:1169-78. PMID 10207169
38: Pietz J, Schmidt E, Matthis P, Kobialka B, Kutscha A, de Sonneville L. EEGs in phenylketonuria 1: follow-up to adulthood; 2: short-term diet-related changes in EEGs and cognitive function. Dev Med Child Neurol 1993;35:54-65. PMID 8449380
39: Pitt DB, Danks DM. The natural history of untreated phenylketonuria over 20 years. J Paediatr Child Health 1991;27:189-90. PMID 1909536
40: Platt LD, Koch R, Hanley WB, et al. The international study of pregnancy outcome in women with maternal phenylketonuriaphenylketonuria: report of a 12-year study. Am J Obstet Gynecol 2000;182(2):326-33. PMID 10694332
41: Poser CM, van Bogaert LV. Neuropathologic observations in phenylketonuria. Brain 1959;82:1-9. PMID 13651489
42: Regier DS, Greene CL. Phenylalanine hydroxylase deficiency. In: Adam MP, Ardinger HH, Pagon RA, et al, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle, 2017. PMID 20301677
43: Ris MD, Williams SE, Hunt MM, Berry HK, Leslie N. Early-treated phenylketonuria: adult neuropsychologic outcome. J Pediatr 1994;124:388-92. PMID 8120707
44: Romani C, Olson A, Aitkenhead L, et al. Meta-analysis of cognitive functions in early-treated adults with phenylketonuria. NeurosciBiobehav Rev 2022;143:104925. PMID 36283539
45: Singh RH, Rohr F, Frazier D, et al. Recommendations for the nutrition management of phenylalanine hydroxylase deficiency. Genet Med 2014;16(2):121-31.** PMID 24385075
46: Smith I, Beasley MG, Wolff OH, Ades AE. Behavior disturbance in 8-year-old children with early treated phenylketonuria. J Pediatr 1988;112:403-8. PMID 3346777
47: Solverson P, Murali SG, Brinkman AS, et al. Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria. Am J Physiol Endocrinol Metab 2012a;302(7):E885-95. PMID 22297302
48: Solverson P, Murali SG, Litscher SJ, Blank RD, Ney DM. Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet. PloS One 2012b;7(9):e45165. PMID 23028819
49: Trefz FK, Burton BK, Longo N, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr 2009;154(5):700-7. PMID 19261295
50: Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med 2014;16(2):188-200.** PMID 24385074
51: Waisbren SE, Hanley W, Levy HL, et al. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. JAMA 2000;283:756-62. PMID 10683054
52: Waisbren SE, Zaff J. Personality disorder in young women with treated PKU. J Inherit Metab Dis 1994;17:584-92. PMID 7837765
53: Walter JH, White FJ. Blood phenylalanine control in adolescents with phenylketonuria. Int J Adolesc Med Health 2004;16(1):41-5. PMID 15148857
54: Weglage J, Funders B, Wilken B, et al. Psychological and social findings in adolescents with phenylketonuria. Eur J Pediatr 1992;151:522-5. PMID 1396915
55: Weglage J, Wiedermann D, Denecke J, et al. Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria. Ann Neurol 2001;50:463-7. PMID 11601498
56: White DA, Waisbren S, van Spronsen FJ. Final commentary: a new chapter. Mol Genet Metab 2010;99(Suppl 1): S106-7. PMID 20123464
57: Woo SL, Lidsky AS, Guttler F, Chandra T, Robson KJ. Cloned human phenylalanine hydroxylase gene allows prenatal diagnosis and carrier detection of classical phenylketonuria. Nature 1983;306:151-5. PMID 6316140

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Kimberly A Chapman MD PhD

Dr. Chapman of George Washington University and Children’s National Rare Disease Institute received honorariums from HemoShear Therapeutics as principal investigator.
See Profile
Debra S Regier MD PhD

Dr. Regier of Rare Disease Institute, Children’s National Medical Center has no relevant financial disclosures to disclose.
See Profile

Editor

Barry Wolf MD PhD

Dr. Wolf of Lurie Children's Hospital of Chicago has no relevant financial relationships to disclose.
See Profile

Former Authors

S Lane Rutledge MD (original author) and Cary O Harding MD

Patient Profile

Age range of presentation: 0 to 23 months
Sex preponderance: male=female
Heredity: heredity typical

heredity may be a factor

autosomal recessive
Population groups selectively affected: Caucasians
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Phenylketonuria: 270.1
ICD-10: Classical phenylketonuria: E70.0
OMIM: Phenylketonuria: #261600

GTP cyclohydrolase (GTPCH) deficiency, autosomal recessive: #233910

6-Pyruvoyl-tetrahydropterin synthase (PTPS) deficiency: #261640

Dihydropteridine reductase (DHPR) deficiency: #261630

Pterin-4a-carbinolamine dehydratase (PCD) deficiency: #264070

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Phenylketonuria

Associated Disorders

Biopterin-deficient hyperphenylalaninemia
Transient hyperphenylalaninemia

Differential Diagnosis

biopterin-deficient hyperphenylalaninemia
elevated phenylalanine levels
defects in neurotransmitter metabolism

Also Relevant

Abnormalities of tetrahydrobiopterin metabolism
Autism spectrum disorder
Childhood movement disorders
Gene therapy of neurogenetic disorders
Intellectual disability
- Microcephaly
- Screening of newborns for neurogenetic abnormalities

Phenylketonuria

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Vanishing white matter disease

Wilson disease

White matter abnormalities in the brain

Hypermethioninemia

POLG-related mitochondrial disorders

Multiple acyl-CoA dehydrogenase deficiency

Medium-chain acyl-CoA dehydrogenase deficiency

Long-chain fatty acid oxidation defects

This is an article preview.
Start a Free Account
to access the full version.